Lantheus reports 'positive' Phase 2 LMI 1195 trial data.
Lantheus Holdings announced "positive" new data from a Phase 2 study of LMI 1195, a fluorine-18 labeled tracer for use in cardiac positron emission tomography to assess myocardial presynaptic sympathetic nerve function. Altered sympathetic nervous system function has been implicated in a broad range of clinical conditions including heart failure and sudden death. The data will be presented during a poster presentation at the American College of Cardiology's 67th Annual Scientific Session on Monday, March 12, 2018 at 9:45 a.m. ET in the Noninvasive Imaging Moderated Poster Theater. The data show that PET imaging with LMI 1195 provides a comparable measure of cardiac sympathetic nerve function and more favorable kinetics for early cardiac imaging as PET imaging with carbon-11 hydroxyephedrine. C11 HED has been used in cardiac PET imaging to characterize SNS integrity and risk-stratify patients with ischemic cardiomyopathy considered for implantable cardiac defibrillators. However, widespread clinical utility is limited due to the short half-life of C11-labeled tracers, which require the onsite availability of a cyclotron. The findings suggest that LMI 1195 yields a comparable estimate of cardiac sympathetic innervation as C11 HED. LMI 1195 retention index and defect score correlated highly with HED. LV-to-lung ratios were comparable between the two tracers. In addition, LMI 1195 seems to offer more favorable kinetics for early cardiac imaging than HED. A significant difference in blood clearance was observed between the two tracers resulting in a LV-to-blood ratio of LMI-1195 higher than HED within the first five minutes following administration.
|Printer friendly Cite/link Email Feedback|
|Date:||Mar 12, 2018|
|Previous Article:||Sino-Global raises $3M in a registered direct offering.|
|Next Article:||Insulet announced coverage win with UnitedHealth, says William Blair.|